Table 4.
Characteristics of the studies (NACT followed by CCRT)
| Author | Year | Location | Sample size | Average age | FIGO stage | NACT regimen | Response rate to treatment | Follow-up (months) |
Survival | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Post-NACT (%) | Post-CCRT (%) | 3-year PFS | 3-year OS | ||||||||
| Our trial | 2022 | China | 50 | 53 (35–68) | IIB-IVA | Weekly cisplatin (40 mg/m2) and paclitaxel (60 mg/m2) for 4 weeks |
CR (10.4%) CR + PR (79.2%) |
CR (72.0%) CR + PR (90.0%) |
28 | 73.6% | 83.9% |
| Singh RB [9] | 2013 | India | 28 | 51 (35–67) | IIB-IVA | Weekly paclitaxel (60 mg/m2) and carboplatin (AUC = 2) for 6 weeks |
CR (7.1%) CR + PR (67.8%) |
CR (85.7%) CR + PR (92.8%) |
12 | - | - |
| McCormack M [10] | 2013 | UK | 46 | 43 (23–71) | IB-IVA | Weekly paclitaxel (80 mg/m2) and carboplatin (AUC = 2) for 6 weeks |
CR (4.5%) CR + PR (72.7%) |
CR (67.4%) CR + PR (90.7%) |
39.1 | 68% | 67% |
| da Costa Samantha Cabral S [8] | 2019 | Brazil | 55 | 48 (22–69) | IIB-IVA | Every 3 weeks Cisplatin (50 mg/m2 *d1) and Gemcitabine (1000 mg/m2 *d1, d8) for 3 cycles |
CR (12.0%) CR + PR (80.0%) |
CR (56.3%) CR + PR (92.7%) |
31.7 | 40.9% | 60.7% |
| Gadducci A [31] | 2017 | Italy | 13 | 55 (35–63) | IIB-IVA | weekly paclitaxel (80 mg/m2) and carboplatin (AUC = 2) for 6 weeks |
CR (0%) CR + PR (76.9%) |
CR (58.3%) CR + PR (91.6%) |
12 | - | - |